Filing Details

Accession Number:
0001104659-24-043249
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-03 20:00:51
Reporting Period:
2024-03-20
Accepted Time:
2024-04-03 20:00:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649904 Rhythm Pharmaceuticals Inc. RYTM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1260835 Paul Christopher German 222 Berkeley Street, 12Th Floor
Boston MA 02116
Corporate Controller & Cao No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-20 1,163 $0.00 1,163 No 4 M Direct
Common Stock Disposition 2024-04-02 368 $41.76 795 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-03-20 1,163 $0.00 1,163 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,487 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  2. The sale reported in this Form 4 was effected pursuant to non-Rule 10b5-1 trading arrangement, as defined in Item 408(a) of Regulation S-K, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.55 to $41.76. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The restricted stock units have vested or will vest as to 25% of the total shares on each of March 20, 2024, March 20, 2025, March 20, 2026 and March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.